CSL (ASX:CSL) share price dips amid $10b acquisition rumours

The biotech giant's share price finished in the red on Thursday.

| More on:
A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in global biotech giant CSL Limited (ASX: CSL) edged lower today and finished more than 1% in the red at $305.23.

CSL held the fort across the day, with intraday prices trading in a narrow spread of $307–$308 before a large set of trades sent its share price as low as $301.11.

Acquisition rumours?

Rumours are circulating that the Aussie biotech is set to buy Vifor Pharma, a Swiss-based company, in a deal that could see CSL fork out $10 billion.

According to reporting from The Australian, CSL might be heading to the capital markets to raise additional equity capital to the tune of $3 billion–$4 billion.

Both CSL and Vifor have been in a game of verbal ping-pong with talks of the acquisition first circulating back in March this year. If the deal goes through, it would mark the CSL's first major acquisition in over 10 years.

It is understood that Bank of America and Goldman Sachs are to be involved with the transaction, and both banks will nab a hefty fee from CSL's capital raise if it is successful.

Vifor states that it aims to be a leader in iron deficiency, nephrology and cardio-renal therapies, with a focus on chronic disease.

It recognised 1.7 billion Swiss Francs in revenue in 2020 and has a market cap of 6.75 billion Swiss Francs ($10.33 billion). For comparison, CSL's market cap is $140.88 billion.

Vifor itself has been busy on the acquisition trail as well, recently confirming it bought 100% of cardio-renal biopharma company, Sanifit Therapeutics on 22 November.

Curiously, former CSL non-executive director, Abbas Hussain – who resigned from CSL's board in June this year – was recently appointed as the new CEO of Vifor Pharma.

Hussain joined the company on 16 August and will hold tenure as Vifor's top executive after serving on CSL's board for 4 years.

Without further clarification from CSL itself, it is unwise to make any speculation on the matter. However, CSL is well capitalised with over $8.3 billion in net assets – of which $1.8 billion is in cash on the balance sheet.

CSL share price snapshot

The CSL share price has climbed almost 1% in the past 12 months and almost 8% this year to date.

In the past week, it has slipped almost 4% but is in the green by 2% in the past month.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »